Lenvima

Lenvatinib, the active ingredient in Lenvima, is a Tyrosine kinase inhibitor presented as a 4 mg, 10 mg, 14 mg, 20 mg tablet for oral use. It is indicated for radioiodine‑refractory differentiated thyroid cancer, hepatocellular carcinoma, renal cell carcinoma and advanced endometrial carcinoma in adult patients.

GNH USA supplies Lenvima as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenvima is a multi‑targeted tyrosine kinase inhibitor used in several solid‑tumour indications.

- Radioiodine‑refractory differentiated thyroid cancer: slows disease progression and improves progression‑free survival. - Hepatocellular carcinoma: provides an oral systemic option for patients not amenable to curative therapies. - Renal cell carcinoma: used as first‑line or subsequent therapy to inhibit tumour angiogenesis. - Advanced endometrial carcinoma: offers a targeted treatment for patients with disease that has progressed after prior therapy.

Lenvima may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Hypertension: elevated blood pressure requiring monitoring and possible antihypertensive therapy. - Diarrhoea: may be mild to moderate, often manageable with supportive care. - Fatigue: persistent tiredness that can affect daily activities. - Decreased appetite: reduced food intake leading to weight loss. - Nausea: occasional upset stomach, may improve with anti‑emetics.

Serious or Rare Side Effects: - Hepatic failure: signs of liver dysfunction such as jaundice or elevated enzymes. - Severe haemorrhage: gastrointestinal or intracranial bleeding events. - Arterial thromboembolism: risk of stroke or myocardial infarction. - Gastro‑intestinal perforation or fistula formation. - Cardiac failure: new or worsening heart failure symptoms. - Proteinuria: significant urinary protein loss indicating renal involvement.

Before initiating Lenvima, clinicians should assess baseline health status and monitor for specific risks.

- Monitor blood pressure: check regularly and treat hypertension promptly. - Assess liver function: obtain baseline labs and repeat during therapy. - Evaluate for proteinuria: perform urine dipstick tests periodically. - Avoid use in pregnancy: drug is contraindicated and classified as Category X. - Discontinue if severe adverse events occur: follow prescriber guidance for dose interruption or cessation. - Store at below 25°C: keep in the original pack, protect from moisture.

Lenvima can interact with other medicines that affect its metabolism or increase bleeding risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise lenvatinib exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic levels. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): increase risk of serious bleeding.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: blood‑pressure control may need adjustment. - Diuretics: can exacerbate electrolyte disturbances. - Other anti‑angiogenic drugs: additive toxicity, especially hypertension and proteinuria.